Drug Profile
Research programme: oral chemotherapeutic - Veloxis Pharmaceuticals/Herlev Hospital
Alternative Names: Oral chemotherapy - Veloxis PharmaceuticalsLatest Information Update: 09 Mar 2020
Price :
$50
*
At a glance
- Originator LifeCycle Pharma
- Developer Veloxis Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Mar 2020 Veloxis Pharmaceuticals has been acquired by Asahi Kasei
- 06 Mar 2013 Discontinued - Preclinical for Cancer in Denmark (PO)
- 07 Jul 2011 LifeCycle Pharma is now called Veloxis Pharmaceuticals